top of page

Free Biopharma Daily Stock Updates - 11/02/21

$XBI $131.26 +1.29%


Covid Updates

$ABCL +4.1% Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19 source

$NRXP -4.4% NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 source

Pipeline Updates

$CRVS +2.7% Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting source

$JAGX -2.8% Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch source

$NOVN +0.3% Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum source

$LABP +0.6% Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis source

$EOLS -4.5% Evolus Initiates Phase II Program with “Extra Strength” Dose for Extended Duration source

$MTCR -4.2% Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH source

$ALDX -4.7% Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease source

$ABOS -2.4% Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference source

$GLTO +2.1% Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer source

$IKNA +9.0% Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930 source

$EQ +3.9% Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting source

$ACIU +6.2% New Data on AC Immune’s Abeta and pTau Clinical Programs in Alzheimer’s Disease To Be Presented at CTAD 2021 source

$BCYC +3.1% Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer source

$IONS -0.1% Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia source

$QURE +7.6% uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease source

$CLNN -12.7% Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial source


Posted by JM

bottom of page